☐ Yes ☐ No

M Yes M No

TYEST NO.

☐ Yas ☐ No

☐ Yes ☐ No

O Yes O No

T Abstract St N/A

C) Abstract 50 N/A

D Absumet 50 N/A

Charles State

Abstract 🔯 N/A

Abstract 50 N/A

Abstract & NA

## Page 1 of 3 APPLICANT'S Attorney Docket: 92114.005US1 Serial No.: 10/607 623 INFORMATION DISCLOSURE CITATION Applicant: Haim Dansmbere (Substitute Form PTO-1449B) Filling Date: 06/27/03 Group Art Unit: 1614 NON PATENT LITERATURE DOCUMENTS Include same of the author (in CAPITAL LETTERS), title of the article (when appropriate), title Examiner £ 184 initials of the item (book, magazine, junrual, serial, symposium, catalog, etc.), date, page(s), values-issue ak number(s), publisher, city and/or country where published. Translation Van Lout, et al., "In Vivo Role of Phagocytic Synovial Lining Cells in Onset of MYGI MIND Experimental Arthritis," Am. J. Pathol., 143:1226-37 (1993). Abstract N N A Rogers, et al., "Monocyte Recruitment and Neoircimal Hyperplasia in Rubbits." Yes No Arteriosclerosis, Thrombosis, and Vascular Biology, 16:1312-18 (1996). Cl Abstract 52 No. Kumiomo, et al., Abstraci, "Experimental Induction of Athero Sclerosis in Guinea-3 CI Yes CI NO. Pigs Fed a Cholosterol Vitamin D-2-Rich Diet" (1983). Abstinct [] N-A no date Pharmaey, 20th Ed., Ch. 41, pp. 780-920. Abstract (X) N/A Pleisch, "Bisphosphonates in bone disease," Parthenon Publishing Group Inc., pp. 5 O Yes O No 184-210 (1997). Abetrar Marca Mak, et al., "Clinical Trials to prevent Restenosis after Perchtaneous Coronary 6. M Yes M No. Revascularization," The NY Academy of Sciences, pp. 225-77 (1994). C Abstract & N/A Leolero, et al., "Drug prevention of restonesis after angioplasty; an undate." Elsevier □ Yok □ No Science, pp. 722-24 (1995). Cl Alicanica (22 N/A Lefkovits, et al., "Pharmacological Approaches for the Prevention of Restenesis ☐ Yes ☐ No After Percutaneous Coronary Intervention," Progress in Cardiovascular Disease, T Abstract St N/A 40(2):141-58 (1997) Hamon, et al., "Resienosis after coronary angioplasty," Eur. Heart J., 16:33-48. MY YOU NO (1995). C Abrama (N N A 10. Gottsauper-Wolf, et al., "Influence of local delivery of the protein tyrosine kinase MY Yes Mi No receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid Alst Kill consider [2] balloon-impry model," Am. Heart J., 19:347-56 (1996). Shioi, et al., "B-Glycerophosphate Accelerates Calcification in Cultured Bovine MYCS MINI Vascular Smooth Muscle Cells," Arteriosclerosis, Thrombosis and Vascular CI Abstract IN NA

Bellah, et al., "Idiopathic arterial calcification of infancy; Prenatal and postnatal

effects of therapy in an infant," The Journal of Pediatrics, 121(6):930-3 (1992).

of Histologic Findings after Various Interventional Procedure - Part VI." Clin.

and bypass grafting," Curr-Opin-Cardiol., 11(6):583-90 (1996).

Waller, et al., "Coronary Artery and Saphenous Vein Graft Remodeling: A Review

Anderson, et al., "A review of randomized trials comparing coronary angioplasty

Moorman, et al., "Percutancous Transluminal Comnary Angioplasty (PTCA): Long-

term Outcome and Aeromedical Implications," Aviation, Space and Environmental

Laurent, et al., "The arterial wall: a new pharmacological and therapeutic target,"

Schwariz, "The vessel wall reaction in restenosis," Semin, Intervent, Cardiol., 2:83-

Allaire, et al., "Endothelial Cell Injury in Cardiovascular Surgery: The Imimal

Hyperplastic Response," Ann. Tharac. Surg., 63(2):582-91 (1997).

12.

13.

14

15.

16

17

18

8 (1497).

Biology, 15(11):2003-9 (1995),

Cardiol., 20:153-60 (1997).

Medicine, 57(10):990-6 (1996).

Fundam, Clin. Pharmacol., 10:243-57 (1996).

Serial No.: 10/607,623

Attorney Docket No.: 92114.005US1

Applicant: Hain: Danenberg

	19,	Webb, et al., "Inhibition of Biognosthetic Heart Valve Calcification with Amimoliphosphonate Covalently Bound to Residual Aldehyde Groups," Ann. Thorax. Surg., 46:509-14 (1988).	□ Yes □ No □ Absence 図 N.A
	<ol> <li>Wagner, et al., "Contrasting Effects of Ethane-1-Hydroxy-1, 1-Diphosphonate (EHDP) on the Regression of two types of Dietary-Induced Atherosolerosis." Atherosolerosis. 27(4):9-5 (1977).</li> </ol>		☐ Yes ☐ No ☐ Abstract Ø AcA
	21.	Daousi, et al., "The effect of chlane-1-hydroxy-1, 1-diphosphouste (EHDP) on necrosis of atherosclerotic lesions," <i>Atherosclerosis</i> , 67:41-8 (1987).	☐ Yos ☐ Net ☐ Abelraci ☒ AcA
	22.	Walsh, et al., "Molecular strategies to inhibit restenosis; modulation of the vascular myocyte phenotype," Semin. Intervent. Cardiol., 1:173-9 (1996).	☐ Yes ☐ No ☐ Abstract ☑ N. A
	23.	Herrman, et al., "Pharmacological Approaches to the Prevention of Restenosis Following Augioplasty," <i>Drugs</i> , 46(1):18-52 (1993).	☐ Yes ☐ No ☐ Abstract ☑ N/A
	24.	Rubin, et al., "Cellular and Molecular Mechanisms of Radiation Inhibition of Restenosis, Part I: Role of the Maurophage and Platelet-Derived Growth Factor," Int. J. Rudiation Oncology Biol. Phys., 40:929-41 (1998).	☐ Yes ☐ No ☐ Absenset 🕲 N/A
	25.	Makkar, et al., "Prevention of Restenesis by Local Drug Delivery," J. Cardiovasc. Pharmacol. Therapeut., 1(2):177-88 (1996).	Yes No
	26.	Arolieva, et al., "Monocyte Integrin Expression and Monocyte-Platelet Complex Formation in Humans with Coronary Restenosis," Clin. Exp. Pharm. Physio., 28:804-8 (2001).	□ Yer □ No □ Abstract ⊠ N/A
***************************************	27.	Bohm, et al., "Exogenous Hepatitis B Surface Antigen Particles Processed by Dendritic Cells or Macrophages Prime Marine MHC Class I-Restricted Cytotoxic T Lymphocytes In Vivo," J. Immunol., 155:3313-21 (1995).	☐ Yes ☐ No ☐ Abstract 図 N/A
	28.	Buiting, et al., "Liposomes as autigen carriers and adjuvants in vivis," Res. Immunol., 143:541-8 (1992).	☐ Yes ☐ No ☐ Abstract ② N/A
	29.	Bergh, et al., "Liposome-mediated nucrophage depletion: an experimental approach to study the role of testicular macrophages in the rat," <i>J. Endocrinol.</i> , 136:407-13 (1993).	☐ Yes ☐ No ☐ Abstonet ❷ N/A
	30.	Van Booijen, et al., "Apoptosis of macrophages induced by liposome-mediated intracellular delivery of electronate and propamidine," J. Immunol. Methods, 193:93-94-9496).	□ Yes □ No □ Aibstract ⊠ N/A
	31.	Leenaars, et al., "Increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination in vivo," <i>Immunol.</i> , 90:337-43 (1997).	☐ Yes ☐ No ☐ Abstract ⊠ N/A
	32.	Yue, et al., "In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Paroxisome Proliferator-Activated Receptor-4 Agonist Rosiglitazone," Circuluman, 104:2588-94 (2001).	☐ Yes ☐ No ☐ Absuzzet ❷ N/A
	33.	Bolb, et al., "Evidence That Late Preconditioning Against Myocardial Stiming in Cosscious Rubbits Is Triggered by the Generation of Nitrie Oxide," Climidation Res., 81:42-52 (1997).	□ Yes □ No □ Abstract ⊠ N/A
	)4.	Zhun, et al., "Myocardial apoptosis and ischemic preconditioning," Cardiovase Res., 55.438-55 (2002).	☐ Yes ☐ No ☐ Abstence 図 No.A
	35.	Van Rooijen, et al., "The miscrophage as target or obstacle in liposome-based targeting strategies," Int. J. Pharmiceu., 162:45-50 (1998).	☐ Yes ☐ No ☐ Abstract 図 N-A
3	36.	Matthews, et al. "Comparison of the response of primary human pertipheral blood monounclent phagocytes from different donors to challenge with model polyethylene particles of known size and dose," Biomaterials, 21:2033-44 (2000).	□ Yok □ No □ Aherres ❷ N/A

Serial No.: 10/607,623

Attorney Booket No.: 92114.005US1

Applicant: Haim Danesberg

	37.	Fisher, et al., "Aleuthronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vino." Cell Biol., 96:133-8 (1999).	☐ Y6. ☐ Na ☐ Absrace ❷ N/A
	38.	Sansoni, et al., "Inhibition of antigen-presenting cell function by alendronate in vitro," J. Bone Min. Res., 10(11):1719-25 (1995).	☐ Yes ☐ No ② Afternoon ☐ NoA
	39.	Lodge-Paick, "The Agoing of Cardiac Infarcts, and its Influence on Cardiac Ruphire," Br. Heart J., pp. 37-42 (1951).	☐ Yes ☐ No ☐ Abstract ※ N/A
	40.	Jalowy, et al., "AT1 receptor blockade in experimental myocardial ischemia/reperfusion," Baste Res. Cardiol., 93(2):85-91 (1998).	☐ Yes ☐ No ☐ Absurses ☒ N; A
	41.	Response filed December 22, 2009 in related patent application 10/871,488 in response to October 29, 2009 Final Office Action.	☐ Yis ☐ No ☐ Abstract ❷ N/A
	42.	Non-Final Office Action in related patent application 11/190,787 dated March 3, 2010.	☐ Yes ☐ No ☐ Abstract ※ N/A
*********	43.	Response filed June 1, 2010 in related patent application 11/190,787 in response to March 3, 2010 Non-Final Office Action.	☐ Yes ☐ No ☐ Abistraca ☑ N/A

Exerciner Signature	/Donna Jagoe/	Date Considered	08/16/2010				
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP \$500.						
Draw line through citation if not in conformance and not considered.							
Include copy of this form with next communication to amplicant.							